Targeting T-type channels in cancer: What is on and what is off?

Anna Visa, Lía Alza, Adrian Casas-Benito, Judit Herreros, Carles Cantí

Journal: Drug discovery today 2022;27(3):743-758

PMID: 34838727

Abstract

Over the past 20 years, various studies have demonstrated a pivotal role of T-type calcium channels (TTCCs) in tumor progression. Cytotoxic effects of TTCC pharmacological blockers have been reported in vitro and in preclinical models. However, their roles in cancer physiology are only beginning to be understood. In this review, we discuss evidence for the signaling pathways and cellular processes stemming from TTCC activity, mainly inferred by inverse reasoning from pharmacological blocks and, only in a few studies, by gene silencing or channel activation. A thorough analysis indicates that drug-induced cytotoxicity is partially an off-target effect. Dissection of on/off-target activity is paramount to elucidate the physiological roles of TTCCs, and to deliver efficacious therapies suited to different cancer types and stages.

Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Address: Universitat de Lleida-IRBlleida, Lleida, Spain.; Universitat de Lleida-IRBlleida, Lleida, Spain. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.